These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7351032)

  • 1. An assay for osteoclast-activating factor (OAF) in biological fluids: detection of OAF in the serum of myeloma patients.
    Luben RA
    Cell Immunol; 1980 Jan; 49(1):74-80. PubMed ID: 7351032
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the effects of 1,25-dihydroxycholecalciferol, prostaglandin E2, and osteoclast-activating factor with parathyroid hormone on the ultrastructure of osteoclasts in cultured long bones of fetal rats.
    Holtrop ME; Raisz LG
    Calcif Tissue Int; 1979; 29(3):201-5. PubMed ID: 117883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor.
    Josse RG; Murray TM; Mundy GR; Jez D; Heersche JN
    J Clin Invest; 1981 May; 67(5):1472-81. PubMed ID: 6262378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.
    Durie BG; Salmon SE; Mundy GR
    Br J Haematol; 1981 Jan; 47(1):21-30. PubMed ID: 7437344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of osteoclast activating factor from human leukocytes on bone metabolism.
    Raisz LG; Luben RA; Mundy GR; Dietrich JW; Horton JE; Trummel CL
    J Clin Invest; 1975 Aug; 56(2):408-13. PubMed ID: 1171115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of the lymphokine osteoclast activating factor requires cyclic AMP accumulation.
    Yoneda T; Mundy GR
    Calcif Tissue Int; 1982 Mar; 34(2):204-8. PubMed ID: 6177386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes.
    Luben RA; Mundy GR; Trummel CL; Raisz LG
    J Clin Invest; 1974 May; 53(5):1473-80. PubMed ID: 4825237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes.
    Yoneda T; Mundy GR
    J Exp Med; 1979 Jan; 149(1):279-83. PubMed ID: 105076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucocorticoids on osteoclast-activating factor.
    Strumpf M; Kowalski MA; Mundy GR
    J Lab Clin Med; 1978 Nov; 92(5):772-8. PubMed ID: 712208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocytes regulate osteoclast-activating factor production by releasing prostaglandins.
    Yoneda T; Mundy GR
    J Exp Med; 1979 Aug; 150(2):338-50. PubMed ID: 458377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of prostaglandin E2 and parathyroid hormone on plasma calcium concentration and osteoclast function.
    Vanderwiel CJ; Talmage RV
    Endocrinology; 1979 Sep; 105(3):588-94. PubMed ID: 467320
    [No Abstract]   [Full Text] [Related]  

  • 12. Big and little forms of osteoclast activating factor.
    Mundy GR; Raisz LG; Shapiro JL; Bandelin JG; Turcotte RJ
    J Clin Invest; 1977 Jul; 60(1):122-8. PubMed ID: 874077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
    Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
    Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta.
    Dewhirst FE; Stashenko PP; Mole JE; Tsurumachi T
    J Immunol; 1985 Oct; 135(4):2562-8. PubMed ID: 3875658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of hybridomas secreting monoclonal antibodies against the lympholine osteoclast activating factor.
    Luben RA; Mohler MA; Nedwin GE
    J Clin Invest; 1979 Jul; 64(1):337-41. PubMed ID: 221547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effects of osteoclast-activating factor (OAF) on the absorption of alveolar bone. 1. Production and purification of OAF (author's transl)].
    Marumoto Y; Kusunoki K; Fijihashi H; Osaka H; Nakamura Y; Ikeda K
    Nihon Shishubyo Gakkai Kaishi; 1982 Mar; 24(1):121-7. PubMed ID: 6980245
    [No Abstract]   [Full Text] [Related]  

  • 17. The cellular basis of bone resorption.
    Chambers TJ
    Clin Orthop Relat Res; 1980 Sep; (151):283-93. PubMed ID: 7418318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypercalcemia in multiple myeloma].
    Takahashi T
    Nihon Rinsho; 1995 Mar; 53(3):710-4. PubMed ID: 7699910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC; Farrugia AN; To LB; Atkins GJ
    Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsecretory multiple myeloma with osteoporosis: immunocytologic and bone resorptive studies.
    Van Slyck EJ; Kleerekoper M; Abraham JP; Deegan MJ
    Am J Med Sci; 1986 May; 291(5):347-51. PubMed ID: 3518452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.